Loading
From Cogent Biosciences's own hiring board · Oct 14, 2026
Who We Are
Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Positive results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST were reported in 2025. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2.
Our Team
https://cogent.culturehq.com
Top roles Associate Director, Patient Marketing ×4 · Director, Corporate Counsel ×4 · Manager, Cost Accounting ×2
Where Waltham, Massachusetts, United States ×11 · Boulder, Colorado, United States ×3 · Remote ×1
Folded from this feed's corpus only. No description of what Cogent Biosciences does, no rating.
Browse Associate Director, Patient Marketing roles across the corpus →
Open roles 15